SELENOK
gene geneOn this page
Also known as SELK
Summary
SELENOK (selenoprotein K, HGNC:30394) is a protein-coding gene on chromosome 3p21.1, encoding Selenoprotein K (Q9Y6D0). Required for Ca(2+) flux in immune cells and plays a role in T-cell proliferation and in T-cell and neutrophil migration.
The protein encoded by this gene belongs to the selenoprotein K family. It is a transmembrane protein that is localized in the endoplasmic reticulum (ER), and is involved in ER-associated degradation (ERAD) of misfolded, glycosylated proteins. It also has a role in the protection of cells from ER stress-induced apoptosis. Knockout studies in mice show the importance of this gene in promoting Ca(2+) flux in immune cells and mounting effective immune response. This protein is a selenoprotein, containing the rare amino acid selenocysteine (Sec). Sec is encoded by the UGA codon, which normally signals translation termination. The 3’ UTRs of selenoprotein mRNAs contain a conserved stem-loop structure, designated the Sec insertion sequence (SECIS) element, that is necessary for the recognition of UGA as a Sec codon, rather than as a stop signal. Pseudogenes of this locus have been identified on chromosomes 6 and 19.
Source: NCBI Gene 58515 — RefSeq curated summary.
At a glance
- GWAS associations: 3
- Clinical variants (ClinVar): 20 total
- MANE Select transcript:
NM_021237
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:30394 |
| Approved symbol | SELENOK |
| Name | selenoprotein K |
| Location | 3p21.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | SELK |
| Ensembl gene | ENSG00000113811 |
| Ensembl biotype | protein_coding |
| OMIM | 607916 |
| Entrez | 58515 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 1 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding
ENST00000485414, ENST00000487571, ENST00000488746, ENST00000495461
RefSeq mRNA: 1 — MANE Select: NM_021237
NM_021237
CCDS: CCDS54597
Canonical transcript exons
ENST00000495461 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000771768 | 53886851 | 53886934 |
| ENSE00000861049 | 53888393 | 53888483 |
| ENSE00001813144 | 53891770 | 53891859 |
| ENSE00001864247 | 53884417 | 53885561 |
| ENSE00003673177 | 53885826 | 53885912 |
Expression profiles
Bgee: expression breadth ubiquitous, 256 present calls, max score 99.37.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.9257 / max 398.8763, expressed in 1804 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 42525 | 23.9257 | 1804 |
Top tissues by expression
256 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| left ventricle myocardium | UBERON:0006566 | 99.37 | gold quality |
| corpus epididymis | UBERON:0004359 | 99.21 | gold quality |
| myocardium | UBERON:0002349 | 99.05 | gold quality |
| tibialis anterior | UBERON:0001385 | 99.00 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 98.97 | gold quality |
| heart right ventricle | UBERON:0002080 | 98.92 | gold quality |
| pancreatic ductal cell | CL:0002079 | 98.85 | gold quality |
| caput epididymis | UBERON:0004358 | 98.84 | gold quality |
| islet of Langerhans | UBERON:0000006 | 98.80 | gold quality |
| deltoid | UBERON:0001476 | 98.62 | gold quality |
| cauda epididymis | UBERON:0004360 | 98.62 | gold quality |
| upper arm skin | UBERON:0004263 | 98.54 | gold quality |
| quadriceps femoris | UBERON:0001377 | 98.50 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 98.46 | gold quality |
| cartilage tissue | UBERON:0002418 | 98.46 | gold quality |
| vastus lateralis | UBERON:0001379 | 98.39 | gold quality |
| adenohypophysis | UBERON:0002196 | 98.25 | gold quality |
| cardiac ventricle | UBERON:0002082 | 98.21 | gold quality |
| heart left ventricle | UBERON:0002084 | 98.19 | gold quality |
| seminal vesicle | UBERON:0000998 | 98.18 | gold quality |
| biceps brachii | UBERON:0001507 | 98.16 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 98.16 | gold quality |
| pituitary gland | UBERON:0000007 | 98.15 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 98.10 | gold quality |
| vena cava | UBERON:0004087 | 97.92 | gold quality |
| bone marrow cell | CL:0002092 | 97.89 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 97.89 | gold quality |
| kidney epithelium | UBERON:0004819 | 97.89 | gold quality |
| adult organism | UBERON:0007023 | 97.89 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 97.88 | gold quality |
Single-cell (SCXA)
Detected in 17 experiment(s), a significant marker in 15.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-29 | yes | 4392.76 |
| E-MTAB-9154 | yes | 1745.94 |
| E-MTAB-10662 | yes | 1361.73 |
| E-MTAB-10485 | yes | 892.27 |
| E-HCAD-4 | yes | 75.04 |
| E-HCAD-1 | yes | 54.21 |
| E-CURD-46 | yes | 43.47 |
| E-MTAB-8410 | yes | 35.13 |
| E-GEOD-125970 | yes | 26.09 |
| E-HCAD-11 | yes | 21.60 |
| E-HCAD-9 | yes | 15.33 |
| E-MTAB-10553 | yes | 8.33 |
| E-CURD-122 | yes | 8.19 |
| E-GEOD-135922 | yes | 8.16 |
| E-MTAB-7303 | no | 1007.87 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
54 targeting SELENOK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-340-5P | 100.00 | 72.50 | 4437 |
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-656-3P | 100.00 | 72.15 | 2788 |
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
| HSA-MIR-381-3P | 99.93 | 71.87 | 2854 |
| HSA-MIR-300 | 99.92 | 71.76 | 2856 |
| HSA-MIR-3119 | 99.92 | 71.34 | 2390 |
| HSA-MIR-6768-5P | 99.92 | 67.36 | 1942 |
| HSA-MIR-10395-5P | 99.86 | 67.35 | 676 |
| HSA-MIR-544A | 99.84 | 68.66 | 1965 |
| HSA-MIR-548AG | 99.77 | 69.25 | 1492 |
| HSA-MIR-8084 | 99.73 | 69.57 | 1760 |
| HSA-MIR-4524A-3P | 99.72 | 66.85 | 2406 |
| HSA-MIR-4699-3P | 99.71 | 70.15 | 3142 |
| HSA-MIR-548M | 99.70 | 68.87 | 1749 |
| HSA-MIR-548AI | 99.69 | 69.24 | 1494 |
| HSA-MIR-548BA | 99.69 | 69.14 | 1514 |
| HSA-MIR-570-5P | 99.69 | 69.24 | 1494 |
| HSA-MIR-1284 | 99.67 | 73.56 | 1353 |
| HSA-MIR-29B-2-5P | 99.67 | 68.98 | 1726 |
| HSA-MIR-6758-3P | 99.57 | 67.55 | 1078 |
| HSA-MIR-142-5P | 99.48 | 70.92 | 2416 |
| HSA-MIR-5590-3P | 99.48 | 70.91 | 2429 |
Literature-anchored findings (GeneRIF, showing 16)
- SelK is a novel antioxidant in cardiomyocytes and is related to the regulation of cellular redox balance. (PMID:16962588)
- Human lymphocyte SelK colocalizes with endoplasmic reticulum biomarker KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum receptor. (PMID:21220695)
- Data suggest that SelK is involved in the Derlin-dependent ERAD of glycosylated misfolded proteins and that the function defined by the prototypic SelK is the widespread function of selenium in eukaryotes. (PMID:22016385)
- Polymorphisms in thioredoxin reductase and selenoprotein K genes and selenium status modulate risk of prostate cancer (PMID:23133653)
- SelK reduces hydrophobic substrates, such as phospholipid hydroperoxides, which are known to damage cell membranes. (PMID:25117454)
- IP3R palmitoylation is a critical regulator of Ca(2+) flux in immune cells and define a previously unidentified DHHC/Selk complex responsible for this process. (PMID:25368151)
- overexpression of SelK can inhibit human cancer cell Matrigel adhesion and migration (PMID:26567579)
- SELK has the dynamic structural features to be defined as a HUB protein able to interact with multiple members. (PMID:26735936)
- miR-544a expression was found to be modulated by selenium treatment, suggesting a possible role in SELK induction by selenium. (PMID:27275761)
- These results hereby imply SelK may regulate the release of Ca(2+) by CHERP and play an important role in the proliferation and differentiation of T cell by TCR stimulation. (PMID:28130108)
- The levels of SelS and SelK were decreased during adipocyte differentiation and were inversely related to the levels of peroxisome proliferator-activated receptor gamma (PPARgamma), a central regulator of adipogenesis. (PMID:30082770)
- Three crystal structures have been reported of a CRL2 substrate receptor, KLHDC2, in complex with the diglycine-ending C-end degrons of an early terminated selenoprotein, SelK, and the N-terminal proteolytic fragment of USP1. (PMID:30526872)
- Selenoprotein K enhances STING oligomerization to facilitate antiviral response. (PMID:37023217)
- Selenium-SelK-GPX4 axis protects nucleus pulposus cells against mechanical overloading-induced ferroptosis and attenuates senescence of intervertebral disc. (PMID:38252317)
- SELENOK-dependent CD36 palmitoylation regulates microglial functions and Abeta phagocytosis. (PMID:38320455)
- SelK promotes glioblastoma cell proliferation by inhibiting beta-TrCP1 mediated ubiquitin-dependent degradation of CDK4. (PMID:39155374)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | selenok | ENSDARG00000100823 |
| mus_musculus | Selenok | ENSMUSG00000042682 |
| rattus_norvegicus | Selenok | ENSRNOG00000078830 |
| caenorhabditis_elegans | WBGENE00012766 |
Protein
Protein identifiers
Selenoprotein K — Q9Y6D0 (reviewed: Q9Y6D0)
All UniProt accessions (2): Q9Y6D0, F8WAX7
UniProt curated annotations — full annotation on UniProt →
Function. Required for Ca(2+) flux in immune cells and plays a role in T-cell proliferation and in T-cell and neutrophil migration. Involved in endoplasmic reticulum-associated degradation (ERAD) of soluble glycosylated proteins. Required for palmitoylation and cell surface expression of CD36 and involved in macrophage uptake of low-density lipoprotein and in foam cell formation. Together with ZDHHC6, required for palmitoylation of ITPR1 in immune cells, leading to regulate ITPR1 stability and function. Plays a role in protection of cells from ER stress-induced apoptosis. Protects cells from oxidative stress when overexpressed in cardiomyocytes.
Subunit / interactions. Interacts with DERL1, DERL2, DERL3 and SELENOS. The SELENOK-SELENOS complex interacts with VCP. Interacts with ZDHHC6.
Subcellular location. Endoplasmic reticulum membrane. Cell membrane.
Tissue specificity. Highly expressed in heart.
Post-translational modifications. Cleaved by CAPN2/m-calpain in resting macrophages but not in activated macrophages. Macrophage activation up-regulates expression of the calpain inhibitor CAST/calpastatin, resulting in inhibition of CAPN2 activity. Truncated SELENOK proteins produced by failed UGA/Sec decoding are ubiquitinated by the CRL2(KLHDC2) complex, which recognizes the diglycine (Gly-Gly) at the C-terminus of truncated SELENOK proteins.
Induction. By ER stress (at protein level). Displays a slow increase with a lag phase of 6 hours but exhibits a dramatic increase after incubation with ER stress agents for more than 12 hours with maximum induction at 24 hours. Also induced by accumulation of misfolded proteins in the ER.
Similarity. Belongs to the selenoprotein K family.
RefSeq proteins (1): NP_067060* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR024491 | Se_SelK/SelG | Family |
Pfam: PF10961
UniProt features (8 total): initiator methionine 1, chain 1, transmembrane region 1, region of interest 1, site 1, non-standard amino acid 1, sequence variant 1, helix 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 6DO3 | X-RAY DIFFRACTION | 2.17 |
Predicted structure (AlphaFold)
No AlphaFold model available for Q9Y6D0 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (1): 81–82 (cleavage; by capn2)
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 236 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GOBP_POSITIVE_REGULATION_OF_LYMPHOCYTE_MIGRATION, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_TUMOR_NECROSIS_FACTOR_SUPERFAMILY_CYTOKINE_PRODUCTION, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_POSITIVE_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_MONONUCLEAR_CELL_MIGRATION
GO Biological Process (22): positive regulation of defense response to virus by host (GO:0002230), calcium ion transport (GO:0006816), response to oxidative stress (GO:0006979), macrophage derived foam cell differentiation (GO:0010742), protein palmitoylation (GO:0018345), endoplasmic reticulum calcium ion homeostasis (GO:0032469), positive regulation of interleukin-6 production (GO:0032755), positive regulation of tumor necrosis factor production (GO:0032760), T cell proliferation (GO:0042098), positive regulation of T cell proliferation (GO:0042102), respiratory burst after phagocytosis (GO:0045728), regulation of calcium-mediated signaling (GO:0050848), regulation of protein transport (GO:0051223), establishment of localization in cell (GO:0051649), intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress (GO:0070059), positive regulation of monocyte chemotactic protein-1 production (GO:0071639), T cell migration (GO:0072678), positive regulation of neutrophil migration (GO:1902624), neutrophil migration (GO:1990266), positive regulation of T cell migration (GO:2000406), monoatomic ion transport (GO:0006811), positive regulation of chemokine production (GO:0032722)
GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)
GO Cellular Component (5): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoplasm | 2 |
| endomembrane system | 2 |
| intracellular membrane-bounded organelle | 2 |
| regulation of defense response to virus by host | 1 |
| metal ion transport | 1 |
| response to stress | 1 |
| foam cell differentiation | 1 |
| protein lipidation | 1 |
| protein acylation | 1 |
| endoplasmic reticulum | 1 |
| intracellular calcium ion homeostasis | 1 |
| positive regulation of cytokine production | 1 |
| interleukin-6 production | 1 |
| regulation of interleukin-6 production | 1 |
| tumor necrosis factor production | 1 |
| regulation of tumor necrosis factor production | 1 |
| positive regulation of tumor necrosis factor superfamily cytokine production | 1 |
| T cell activation | 1 |
| lymphocyte proliferation | 1 |
| T cell proliferation | 1 |
| regulation of T cell proliferation | 1 |
| positive regulation of lymphocyte proliferation | 1 |
| positive regulation of T cell activation | 1 |
| respiratory burst involved in defense response | 1 |
| calcium-mediated signaling | 1 |
| regulation of intracellular signal transduction | 1 |
| protein transport | 1 |
| regulation of transport | 1 |
| regulation of establishment of protein localization | 1 |
| establishment of localization | 1 |
| cellular localization | 1 |
| response to endoplasmic reticulum stress | 1 |
| intrinsic apoptotic signaling pathway | 1 |
| positive regulation of chemokine production | 1 |
| monocyte chemotactic protein-1 production | 1 |
| regulation of monocyte chemotactic protein-1 production | 1 |
| lymphocyte migration | 1 |
| positive regulation of leukocyte migration | 1 |
| regulation of neutrophil migration | 1 |
| neutrophil migration | 1 |
Protein interactions and networks
STRING
1266 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SELENOK | SELENOS | Q9BQE4 | 961 |
| SELENOK | SELENOT | P62341 | 918 |
| SELENOK | SELENOO | Q9BVL4 | 917 |
| SELENOK | SELENON | Q9NZV5 | 914 |
| SELENOK | SECISBP2 | Q96T21 | 900 |
| SELENOK | ZDHHC6 | Q9H6R6 | 893 |
| SELENOK | SELENOF | O60613 | 892 |
| SELENOK | SELENOH | Q8IZQ5 | 878 |
| SELENOK | SELENOM | Q8WWX9 | 874 |
| SELENOK | MSRB1 | Q9NZV6 | 865 |
| SELENOK | SELENOW | P63302 | 858 |
| SELENOK | SELENOV | P59797 | 854 |
| SELENOK | SEPHS2 | Q99611 | 844 |
| SELENOK | SELENOI | Q9C0D9 | 811 |
| SELENOK | VCP | P55072 | 804 |
IntAct
101 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| SELENOK | FFAR2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SELENOK | MTIF3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SELENOK | CPLX4 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SELENOK | TMX2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SELENOK | MRM1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 | |
| BIK | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMPRSS2 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| AQP6 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC10A1 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| AMIGO1 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| REEP4 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC35E3 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| GORAB | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| IL10RA | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| ERGIC3 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| MFSD6 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| FFAR2 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| MMD | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| MTIF3 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| FAM209A | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| MUC1 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| RNF19B | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| STOM | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| C6orf47 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPX8 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
| CPLX4 | SELENOK | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (70): SELK (Affinity Capture-MS), SELK (Two-hybrid), SELK (Affinity Capture-Western), VIMP (Affinity Capture-Western), SELK (PCA), SELK (Two-hybrid), SELK (Affinity Capture-MS), SELK (Affinity Capture-MS), SELK (Affinity Capture-RNA), SELK (Reconstituted Complex), VCP (Affinity Capture-Western), SELK (Affinity Capture-MS), SELK (Affinity Capture-Western), PPARG (Reconstituted Complex), PPARG (Affinity Capture-Western)
ESM2 similar proteins: A2VDK6, A2VDV9, F1SR90, O15126, O15127, O77735, P04973, P04975, P08082, P09496, P09497, P56603, P59798, Q01H83, Q0P5B1, Q2EN82, Q2KI76, Q2M146, Q32PE3, Q3C2P8, Q4R8M1, Q5R491, Q5RDN2, Q5REX0, Q5U2R7, Q641S4, Q66I79, Q6GR00, Q6IRU5, Q6PCP5, Q6S9C4, Q7RWT0, Q7Z698, Q86T20, Q8R043, Q8VHI6, Q8VHV8, Q91Y53, Q92968, Q96BY9
Diamond homologs: P59798, Q01H83, Q2EN82, Q32PE3, Q4R8M1, Q55EX3, Q641S4, Q66I79, Q6S9C4, Q9JLJ1, Q9Y6D0
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
20 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 13 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
652 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 3:53885557:TTTAC:T | acceptor_gain | 1.0000 |
| 3:53885558:TTAC:T | acceptor_gain | 1.0000 |
| 3:53885559:TAC:T | acceptor_gain | 1.0000 |
| 3:53885560:AC:A | acceptor_gain | 1.0000 |
| 3:53885561:CC:C | acceptor_gain | 1.0000 |
| 3:53885562:C:CC | acceptor_gain | 1.0000 |
| 3:53885828:T:TA | donor_gain | 1.0000 |
| 3:53886845:CTGTA:C | donor_loss | 1.0000 |
| 3:53886847:GTACC:G | donor_loss | 1.0000 |
| 3:53886848:TAC:T | donor_loss | 1.0000 |
| 3:53886849:A:AC | donor_gain | 1.0000 |
| 3:53886849:A:AT | donor_loss | 1.0000 |
| 3:53886849:AC:A | donor_gain | 1.0000 |
| 3:53886850:C:CA | donor_loss | 1.0000 |
| 3:53886850:C:CC | donor_gain | 1.0000 |
| 3:53886850:CC:C | donor_gain | 1.0000 |
| 3:53886850:CCCT:C | donor_gain | 1.0000 |
| 3:53886853:T:A | donor_gain | 1.0000 |
| 3:53886856:T:TA | donor_gain | 1.0000 |
| 3:53886857:C:A | donor_gain | 1.0000 |
| 3:53886930:TGAAA:T | acceptor_gain | 1.0000 |
| 3:53886931:GAAA:G | acceptor_gain | 1.0000 |
| 3:53886932:AAAC:A | acceptor_loss | 1.0000 |
| 3:53886933:AA:A | acceptor_gain | 1.0000 |
| 3:53886933:AACTG:A | acceptor_loss | 1.0000 |
| 3:53886934:AC:A | acceptor_loss | 1.0000 |
| 3:53886935:C:CC | acceptor_gain | 1.0000 |
| 3:53886941:C:CT | acceptor_gain | 1.0000 |
| 3:53886942:A:T | acceptor_gain | 1.0000 |
| 3:53888391:A:AC | donor_gain | 1.0000 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000869919 (3:53884060 G>A), RS1001156667 (3:53884421 C>T), RS1001312325 (3:53887322 G>A,C), RS1001411475 (3:53886745 G>A), RS1002285068 (3:53892658 G>A,T), RS1002439078 (3:53891525 C>T), RS1003695311 (3:53891679 C>G,T), RS1003746434 (3:53885315 T>A,C), RS1003799077 (3:53884991 A>G), RS1003852523 (3:53892697 A>T), RS1004447584 (3:53888237 C>A), RS1004514614 (3:53891128 C>G), RS1004595938 (3:53889451 G>A), RS1005195240 (3:53887849 G>A), RS1005300685 (3:53893768 G>A)
Disease associations
OMIM: gene MIM:607916 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
3 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002115_6 | Axial length | 8.000000e-06 |
| GCST005951_50 | Body mass index | 5.000000e-11 |
| GCST009391_1301 | Metabolite levels | 7.000000e-07 |
EFO canonical traits (3, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0005318 | axial length measurement |
| EFO:0004340 | body mass index |
| EFO:0010517 | oxalate measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
43 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases expression, decreases expression, affects cotreatment, increases abundance | 3 |
| Estradiol | affects cotreatment, increases expression, decreases expression | 3 |
| Tobacco Smoke Pollution | increases expression | 3 |
| Cyclosporine | increases expression | 3 |
| bisphenol F | affects cotreatment, increases methylation | 1 |
| dicrotophos | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| beta-lapachone | increases expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| cobaltous chloride | increases expression | 1 |
| manganese chloride | increases abundance, increases expression, affects cotreatment | 1 |
| cupric chloride | increases expression | 1 |
| nickel sulfate | increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| (4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) | increases expression | 1 |
| NSC 689534 | affects binding, increases expression | 1 |
| MT19c compound | increases expression | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | decreases expression | 1 |
| Bortezomib | increases expression | 1 |
| Fulvestrant | increases methylation, affects cotreatment | 1 |
| Norethindrone Acetate | affects cotreatment, increases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Air Pollutants, Occupational | increases expression | 1 |
| Arsenic | increases expression, affects cotreatment, increases abundance | 1 |
| Cisplatin | increases expression | 1 |
| Copper | affects binding, increases expression | 1 |
| Diuron | decreases expression | 1 |
| Doxorubicin | increases expression | 1 |
Cellosaurus cell lines
3 cell lines: 3 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_TK52 | HAP1 SELK (-) 1 | Cancer cell line | Male |
| CVCL_TK53 | HAP1 SELK (-) 2 | Cancer cell line | Male |
| CVCL_TK54 | HAP1 SELK (-) 3 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.